In fact, TNBC represents the predominant tumor type in patients with BRCA1 mutations, accounting for 71% (range 42-100%) of tumors, while TNBC has been diagnosed in only 25% of patients with germline BRCA2 mutations [33]. The gene discussed is BRCA1; the disease is neoplasm.